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A liquid chromatography (LC) method for the quantification of tretinoin (TTN) in different matrices (adhesive
tape, cotton and porcine skin layers, stratum corneum, viable epidermis, and dermis) was validated and applied in
in vitro porcine skin penetration/retention studies. This study proposes, for the first time, a method for assaying
TTN in separated porcine skin layers (stratum corneum, viable epidermis, and dermis). The skin studies were
carried out using tape stripping and cutaneous retention techniques. The procedures for the extraction of TTN
from dermatological formulations (creams and gels) and biological and non-biological matrices used with the tape
stripping and retention techniques were also evaluated. The LC method consisted of a mobile phase composed of a
mixture of methanol, water, and glacial acetic acid (85:15:1, v/v); a C18 column used as the stationary phase; a
flow rate of 1.0 mL min1; an injection volume of 100 μL; and TTN detection at 342 nm. The method was linear in
the range of 0.05–15.00 μg mL1 (r ¼ 0.9999), and it was precise and accurate. The limit of detection (LOD) and
limit of quantification (LOQ) were 0.0165 μg mL1 and 0.0495 μg mL1, respectively. TTN was extracted from
different matrices, showing good precision [relative standard deviation (RSD) of <5%] and accuracy
(89.4–113.9%). This method was successfully applied in the evaluation of TTN skin retention/permeation from
dermatological formulations (cream and gel). A higher penetration of TTN through the skin was achieved with the
gel rather than the cream, showing the influence of the dosage form. Therefore, the developed method can easily
be applied in porcine skin penetration/retention studies of dermatological formulations containing TTN, and it is
able to discriminate the behaviours of the different formulations.1. Introduction
Tretinoin (TTN), also called retinoic acid, is a retinoid, and it is an
active component of the metabolism of vitamin A. It has been widely
used in dermatological products due to its efficacy in the treatment of
cutaneous diseases, such as acne, ichthyosis, psoriasis, and skin cancer, as
well as its anti-aging effects [1, 2]. The percutaneous absorption of TTN
from dermatological formulations should be avoided during product
development. This can be explained by its well-documented teratogenic
effects after oral or topical administration [3, 4], even though it has a low
percutaneous absorption of about 1% [5, 6]. On the other hand, it is
important to consider that substances for the treatment of skin cancer and
psoriasis, as well as those for anti-aging uses, must be able to penetrate
deeper skin layers in order to reach their target sites [7].
Skin permeation/penetration studies have been widely used to eval-
uate the safety of dermatologic and cosmetic products [8, 9]. Several.
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is an open access article under tmethods have been used to evaluate drug penetration from topical and
transdermal formulations, such as autoradiography [10], Franz diffusion
cells [11, 12], microdialysis [13], skin biopsy [14], tape stripping [15],
and cutaneous retention [16]. The tape stripping technique is a simple,
efficient, and quick method to assess drug distribution through the skin
layers following application of topical dermatological formulations [17].
Tape stripping, which allows for drug quantification in the stratum cor-
neum, and the cutaneous retention technique have been previously used
in TTN skin penetration studies [16, 18, 19, 20].
Regardless of the technique, an adequate analytical method to assay
the drug, which should be specific, precise, and accurate, must be used
[21]. When choosing a method, it is important to consider that a small
amount of drug is expected in the different skin layers. Therefore, these
analytical methods should have a low limit of quantification [22].
Moreover, dermatological formulations are formulated as semisolid18 December 2019
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matrices [23], along with the different components of the skin layers.
To the best of our knowledge, there is still a lack of validated, simple,
and suitable methods to assay TTN in different porcine skin layers for
penetration/retention studies from dermatological formulations, such as
creams and gels. Most studies have not evaluated TTN penetration in
different skin layers, separately [24, 25, 26], or they used other skin
models [27, 28]. Porcine is the most used skin model for pene-
tration/permeation studies due to its similarity to human skin in terms of
its anatomical and physiological characteristics [29, 30]. Therefore, the
goal of this study was to validate an analytical method used to assay TTN
in different matrices (dermatological formulations, cotton, tape, and
skin) as well as to set up the protocol for TTN extraction from these
matrices. This method was applied in skin penetration/retention studies
from semisolid dosage forms (cream and hydrogel) using the tape strip-
ping and cutaneous retention techniques. The influence of the semisolid
dosage form on TTN distribution through the skin layers was evaluated in
order to determine the feasibility of using this method to discriminate the
different behaviours of the formulations.
2. Materials and methods
2.1. Materials
TTN was purchased from PharmaNostra (S~ao Paulo, Brazil). Carbo-
pol® Ultrez 10 NF was obtained from Fragon (S~ao Paulo, Brazil). Imi-
dazolydinil urea, triethanolamine, propylene glycol, methylparaben,
propylparaben, glyceryl monostearate, isopropyl miristate, stearic acid,
almond kernel oil, liquid paraffin, and polyethylene glycol 400 were
obtained from Delaware (Porto Alegre, Brazil). Polysorbate 80 was pur-
chased from Henrifarma (S~ao Paulo, Brazil). Glacial acetic acid was ac-
quired from LabSynth (Diadema, Brazil). Hydrophilic cotton was
purchased from Cremer (Blumenau, Brazil). Durex™ adhesive tapes were
obtained from 3M (Sumare, Brazil). Methanol (HPLC grade) was ac-
quired from Tedia Brazil (Rio de Janeiro, Brazil). Ultrapure water was
used to prepare all formulations (Milli-Q, Millipore, USA). All reagents
were of analytical or chromatographic grade. The porcine skin used in
the penetration/retention studies was donated by a local slaughterhouse
(Araldi, Nova Roma do Sul, Brazil).
2.2. Methods
2.2.1. Preparation and characterisation of the dermatological formulations
In this study, the dermatological formulations were prepared at our
laboratory. They were designed to avoid the use of high amount of
alcohol to disperse TTN and that could affect TTN skin permeation/
penetration behaviour. Moreover, this approach makes easier the prep-
aration of the respective blank formulations, prepared without TTN, for
the method validation studies.
Creams were prepared (n¼ 3) as an O/W (oil in water) emulsion. The
oil phase containing stearic acid (4%, w/v), glyceryl monostearate (6%,
w/v), isopropyl miristate (2%, w/v), liquid paraffin (1%, w/v), almond
kernel oil (0.5%, w/v), and propylparaben (0.2%, w/v) was heated to 70
C in a mortar. Then, an aqueous phase composed of methylparaben
(0.1%, w/v), propylene glycol (3%, w/v), triethanolamine (0.2%, w/v),
and ultrapure water (83 mL) was heated to 75 C and added to the oil
phase under gentle shaking using a pestle. The homogenisation was
maintained until the temperature of the emulsion reached 30 C. TTN-
loaded creams (TTN-C) were prepared (n ¼ 3) with the addition of
0.05 g of TTN to 99.95 g of the previously prepared creams under gentle
homogenisation using a mortar and pestle. Blank-creams (B-C), without
any TTN, were used as control.
Gels were prepared (n ¼ 3) through the dispersion of 0.5% (w/v)
Carbopol® Ultrez 10 NF in ultrapure water. Imidazolydinil urea (0.5%,
w/v) was added as a preservative. During the last step, the polymeric
dispersion was neutralised with 120 μL of triethanolamine, reaching a pH2
of 5.5–6.0. TTN-loaded gels (TTN-G) were prepared (n ¼ 3) by adding
0.05 g of TTN [previously dispersed in propylene glycol at 3% (w/v)] to
99.95 g of the previously prepared gel under gentle homogenisation
using a mortar and pestle. In order to avoid any degradation of TTN, all
procedures were carried out by protecting the samples from light. Blank-
gels (B-G), without any TTN, were used as control.
The pH values, drug contents, and rheological measurements were
determined for all formulations. The pH values of the formulations were
measured using a calibrated pH meter (Ultrabasic, Denver Instrument,
NY, USA) after dilution of the samples in water (10%, w/v). The rheo-
logical behaviour of the semisolid formulations was evaluated using a
rotational viscometer (LVDV-II þ PRO Digital Viscometer, Brookfield
Instruments, UK) and a SC4-25 spindle. Analyses were carried out at 25
1 C. The drug content of the hydrogels was assessed using liquid chro-
matography (LC) by employing a previously validated method [12].
2.2.2. Preparation of the porcine skin membrane
Female abdominal porcine skin was kindly donated by a local
slaughterhouse (Araldi, Nova Roma do Sul, Brazil). The adipose tissue
was carefully removed. Then, the skin surface was cleaned using 1 % (w/
v) sodium lauryl sulphate. Skin slices were cut into circles (3.5 cm
diameter), and their thicknesses were measured using a dial thickness
gage. Skin slices with 1.7  0.3 mm thickness were used. Skin samples
were wrapped in aluminium foil and stored in a freezer (–4 C). They
were not stored for a period longer than 90 days. Before the studies, the
skin samples were left at room temperature for 30 min.
2.2.3. High-performance liquid chromatography (HPLC) system
The chromatographic system consisted of a Shimadzu® LC-20A sys-
tem, a 20AT pump, a CBM-20A system controller, an SPD-M20A photo-
diode array detector, and an SIL-20A auto-sampler (Shimadzu, Tokyo,
Japan). Chromatographic separation was obtained using an analytical
column (C18, 150  4.6 mm, 5 μm, Phenomenex®) coupled to a pre-
column (C18, 4.0  3.0 mm, Phenomenex®). The mobile phase con-
sisted of a mixture of methanol and water (85:15) with 1% glacial acetic
acid. The mobile phase was filtered, degassed, and pumped at a flow rate
of 1.0 mLmin1. The injection volumewas 100 μL, and TTNwas detected
at 342 nm. The LC method validated in this study for application in
porcine skin permeation/penetration studies was based on work by
Ourique et al. [12], with some modifications.
2.2.4. Validation of the analytical method for skin penetration studies of
tretinoin
Validation of this methodology for quantification of TTN was per-
formed for samples of the following different matrices used in skin
penetration/retention studies: formulations, adhesive tapes (used for the
tape stripping protocol), porcine skin membranes, and cotton pieces
(used to remove excess formulation on the skin membranes at the end of
the experiment). The following parameters were evaluated: specificity,
linearity, limit of detection (LOD), limit of quantification (LOQ), intra-
and inter-day precision, and accuracy, as recommended by the guidelines
of the International Conference on Harmonization of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use (ICH)
[31].
2.2.4.1. Specificity. The specificity of the chromatographic method was
evaluated for matrices without the drug (B–C and B–G), which were
submitted to the extraction process proposed in this study (section
2.2.4.5) in order to demonstrate that there was no interference in the
retention time of the TTN. This parameter was demonstrated by
comparing the chromatograms obtained from samples containing blank
matrices and samples spiked with a methanolic solution of the drug.2.2.4.2. Linearity. The linearity was evaluated from three analytical
curves (n ¼ 3) at eight concentrations of TTN, from 0.05–15.00 μg mL–1.
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with 1.00 mg mL–1 of TTN was obtained by dissolving 0.025 g of TTN in
25 mL of methanol and sonicating for 3 min. Eight dilutions were pre-
pared at TTN concentrations of 0.05, 0.10, 0.50, 1.00, 2.50, 5.00, 10.00,
and 15.00 μg mL–1. Afterwards, each sample was filtered (0.45 μm) and
assayed by HPLC. The peak areas were plotted versus each drug con-
centration. The analytical curve and the linear correlation coefficient (r)
were determined from linear regression analysis. For analysis of variance
(ANOVA), Windows Excel (2010) software was used, and a 95% confi-
dence interval was considered [31].
2.2.4.3. Limit of detection (LOD) and limit of quantification (LOQ). The
LOD and LOQ were calculated from the slope (s) and the standard de-
viation of the intercept of the analytical curves (S), according to the
following equations [31]:
LOD¼ 3:3 x s
S
(1)




LOD means “limit of detection”;
LOQ means “limit of quantification”;
s is the slope of the analytical curves; and
S is the standard deviation of the intercept of the analytical curves.
2.2.4.4. Precision. The precision of the analytical method was evaluated
in terms of intra-day (repeatability) and inter-day precision (intermedi-
ate precision) for TTN samples in methanolic solutions and in dermato-
logical formulations (TTN-C and TTN-G). Nine replicates (n ¼ 9) of each
formulation were evaluated at a TTN concentration of 10 μg mL–1. The
intra-day precision and inter-day precision of the method were expressed
as the relative standard deviation (RSD ¼ standard deviation/mean 
100). The samples were prepared at 10 μg mL1 of TTN by weighing 0.5 g
of TTN-C or TTN-G in a 25 mL volumetric flask containing methanol.
Afterwards, the samples were submitted to the extraction process
(Table 1), filtration (0.45 μm), and the drug assay by LC using the
chromatographic conditions described above.
2.2.4.5. Accuracy. Before TTN skin penetration/retention studies, TTN
recovery from the different matrices (formulations, porcine skin, adhe-
sive tapes, and cotton pieces) was validated. The adhesive tapes were
used to remove the stratum corneum in the tape stripping technique, while
the cotton pieces were used to remove excess formulation on the skin
surface. The extraction parameters used in this step are presented in
Table 1. Afterwards, each sample was filtered (0.45 μm), and the amount
of drug was assayed by LC according to the method described in section
2.2.3. The accuracy of the analytical method was evaluated from repli-
cates of three different TTN concentrations and expressed as the ratio of
the experimental drug concentration to the corresponding theoretical
drug concentration.
The samples of the dermatological formulations were prepared by
weighing 0.20 g of B–C or B–G in a 10 mL volumetric flask, while addingTable 1. Parameters used in the tretinoin extraction from different matrices.
Sample Vortex mixing Sonication Centrifugation
Time Time  C Time g
Formulation — 30 min 34 30 min 4500
Porcine skin 2 min 30 min 34 30 min 4500
Adhesive tapes 2 min 4 min 34 30 min 4500
Cotton pieces 2 min 30 min 34 15 min 4500
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a known amount of a methanolic solution of TTN to reach final con-
centrations of 5.00, 10.00, and 15.00 μg mL–1. The samples were pre-
pared in triplicate. The samples of the adhesive tapes were transferred to
tubes and contaminated with known amounts of a methanolic solution of
TTN to reach final concentrations of 2.50, 5.00, and 10.00 μg mL–1. The
samples were prepared in triplicate.
Moreover, porcine skins (3 cm diameter) were contaminated with
known amounts of TTN methanolic solution. Afterwards, the skin
remained in contact with the drug for 30 min in a dark environment.
After this time, each skin was cut into small pieces and transferred to
tubes, adding an adequate volume of methanol to reach 9 mL at final TTN
concentrations of 5.00, 10.00, and 15.00 μg mL–1. The experiments were
performed in five determinations. The samples of cotton containing the
formulations were prepared by weighing either TTN-C or TTN-G (0.05%,
w/v) into tubes containing cotton pieces, and a sufficient amount of
methanol for reaching TTN concentrations of 2.50, 5.00, and 10.00 μg
mL–1 was added.
2.2.5. Application of the validated analytical method in skin penetration/
retention studies
Skin penetration/retention studies of TTN from dermatological bases
(TTN-C and TTN-G) were carried out using automated Franz-type vertical
diffusion cells (Franz Microette Plus-Hanson Research® Cell) with a 7 mL
cell receptor compartment and a diffusion area of 1.766 cm2 [32,33]. The
abdominal porcine skin membranes were cleaned and stored as previ-
ously described in section 2.2.2. At the beginning of the experiment, 250
 3.8 mg of TTN-C or TTN-G was applied on the full thickness abdominal
porcine skin membranes, which was mounted in Franz diffusion cells.
The receptor compartment was filled with ethanol/phosphate buffer at
pH 7.4 (70:30, v/v). The experiment was carried out for 12 h. At the end
of the experiment, the diffusion cells were disassembled to assay TTN in
different skin layers (stratum corneum, viable epidermis, and dermis), as
well as in the receptor compartment.
After removing excess formulation on the skin membrane with cotton
pieces, the stratum corneum was removed by the tape stripping technique
using 18 tapes (3M, Durex™), as described by Beber et al. [34]. Each tape
was pressed onto the membrane and then rubbed with a spatula to
remove the stratum corneum. The tapes were transferred to a tube con-
taining 4 mL of methanol. After removal of the stratum corneum by tape
stripping, the viable epidermis was separated from the dermis by im-
mersion of the porcine membrane in ultrapure water heated at 60 C for
45 s [31,32]. Subsequently, the epidermis was removed by scalpel blade
scraping, while the dermis was cut into small fragments [31, 32]. Both
layers were transferred to a tube containing 9 mL of methanol. All
samples were submitted to the extraction process (Table 1) and then
filtered (0.45 μm), and TTN was assayed by the LC method described in
section 2.2.3. The analyses were performed in sextuplicate.
Skin penetration/retention analyses were performed by comparing
the amount of TTN that penetrated (μg/cm2) through the different layers
of the skin (stratum corneum, viable epidermis, and dermis). Excess TTN
on the skin discs (removed using cotton pieces) was quantified at the end
of the experiment in order to verify the percent recovered (%) after part
of the drug penetrated the skin.
2.2.6. Drug release studies
Drug release studies from the semisolid formulations were carried out
using the same conditions described in the skin permeation/penetration
studies (section 2.2.5), replacing the skin discs with membrane discs
(MW of 12,400 kDa; Sigma-Aldrich, USA).
2.2.7. Statistical analysis
The results are expressed as the mean standard deviation (SD). Data
were evaluated by one-way ANOVA and/or the Student-t test. For the in
vitro penetration/retention studies, the data were assessed by ANOVA
followed by Tukey's post-tests, considering a significance level at p <
Figure 1. Rheological profiles (viscosity versus shear rate) of creams and gels
produced containing or not TTN (n ¼ 3). B-C: blank cream; TTN-C: tretinoin-
loaded cream; B-G: blank gel; and TTN-G: tretinoin-loaded gel.
D. de Oliveira et al. Heliyon 6 (2020) e030980.05. All analyses were performed using GraphPad Prism software
(version 5.0).
3. Results and discussion
The aim of this study was to validate a method to assay TTN in
different matrices for its application in skin penetration/retention
studies. Methods designed for this purpose, which are able to evaluate
the amount of TTN in the stratum corneum, viable epidermis, and the
dermis, separately, through skin penetration studies, are lacking. Reli-
able data from these studies are essential to improving the efficacy and
safety of dermatological formulations containing TTN. Therefore, this
study was organised into the following three steps: a) preparation and
characterisation of two semisolid formulations used as models in this
approach; b) validation of the analytical method comprising different
matrices involved in the skin penetration/retention studies; and c)
application of the method in real in vitro skin penetration/retention
studies using porcine skin as a model.
3.1. Physicochemical properties of the formulations (creams and gels)
Creams and gels were prepared using excipients approved for cuta-
neous use and widely employed in the preparation of semisolid dosage
forms. Formulations containing TTN or formulations not containing TTN
were produced. Table 2 shows their physicochemical and organoleptic
properties. Regarding their appearance, the presence of TTN makes the
creams and gels slightly yellow due to its own colour. The presence of the
drug did not affect the pH range of the formulations, regardless of their
semisolid type (cream or gel). Moreover, both formulations containing
TTN (TTN-C and TTN-G) showed a drug content near the expected value
of 0.50 mg/g.
In studies of the skin permeation/penetration behaviour of semisolid
formulations, considering the influence of their rheological profiles on
drug release and, consequently, drug penetration is highly recom-
mended. Figure 1 shows the rheological behaviour for all the formula-
tions developed in this study. All showed non-Newtonian pseudoplastic
rheological behaviour since there was no linear correlation between the
shear stress (Pa) and shear rate (s1) [35], and the viscosity decreased
with increasing shear rate. This behaviour is recommended for derma-
tological formulations since the flow resistance tends to be low for the
application of medium to high shear forces [36]. On the other hand, as
can be visualised in Figure 1, the shear stress at the same shear rate (0.6
s1) was higher for the gels compared to the creams, which means that
these creams have a lower consistency compared to the gels, regardless of
the presence of TTN.
3.2. Validation of the analytical methodology used to assay tretinoin in
different matrices
In order to develop an analytical method that meets the requirements
necessary for application in medicine, as well as to ensure the reliability
of the data obtained, the methodology must be validated through
experimental studies [37]. According to Ribani et al. [38], the specificityTable 2. Physicochemical properties of the semisolid formulations (mean  SD).
B-C: blank cream; TTN-C: tretinoin-loaded cream; B-G: blank gel; and TTN-G:
tretinoin-loaded gel.
Formulation pH Drug content
(mg/g)
Aspect
B-C 7.50  0.01 —— Opalescent, white
TTN-C 7.30  0.08 0.52  0.08 Opalescent, slighly yellow
B-G 5.70  0.11 —— Transparent, colorless
TTN-G 5.90  0.08 0.53  0.03 Slighly opalescent, slighly yellow
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should be the first parameter evaluated. For in vitro per-
meation/penetration studies, different matrices must be considered, such
as the drug vehicles (formulations), cotton pieces, adhesive tapes, and
skin. In this study, the mobile phase, composed of methanol, water, and
glacial acetic acid (85:15:1, v/v), was able to separate the TTN from the
components of the different matrices, as shown in Figure 2A–F. The
matrices did not show any chromatographic peaks at the retention time
for TTN (approximately 15 min). The proposed method was specific for
TTN since no interferences were observed when the chromatograms
obtained from the blank matrices were compared to that of the drug
(Figure 2A).
In the next step, three independent analytical curves were prepared
and analysed in the concentration range of 0.05–15.00 μg mL1. The
regression equation was y ¼ 626420x – 2126.2 (r ¼ 0.9999). These re-
sults indicate that the response of the method was linearly proportional
to the analyte concentration. A good quality standard curve was obtained
due to the correlation coefficient (r) value being greater than 0.99 [37].
In addition, the calculated LOD and LOQ values were 0.0165 and 0.0495
μg mL1, respectively, reflecting the sensitivity of the method. The
concentration determined for the LOQ was very low, which is one
advantage if considering this method for quantification of a drug with
low skin penetration, facilitating evaluation in different skin layers [39].
Intra-day (1.29%) and inter-day precision (0.99%) for samples of TTN in
methanolic solution were less than 5%, as required by ICH for these as-
says [31, 37]. Moreover, the intra-day precision and inter-day precision
of the samples of TTN extracted from the semisolid formulations were
also evaluated (Table 3). A suitable precision for the assay of the drug in
the formulations was obtained (RSD<5%).
The accuracy of the method was evaluated using the recovery test.
Data are presented in Table 4. The recovery (%) ranged from 89.4 to
114.3% of TTN from the different matrices. The TTN extraction results
from the different matrices were within the range specified (80–120%)
by the official agencies [31] for complex matrices. Therefore, the method
was accurate enough to assay TTN in different matrices.
3.3. Application of the validated analytical method in skin permeation/
retention studies
After validating the method, its applicability was demonstrated in a
real experiment. Therefore, the skin permeation/retention of TTN from a
gel and a cream was evaluated using porcine skin. TTN did not permeate
to the receptor compartment from any formulation. Figure 3 shows the
results of TTN skin penetration/retention studies from TTN-C and TTN-G.
A higher concentration of TTN was found in the stratum corneum for both
formulations, followed by a decrease in drug flow to the adjacent skin
layers, evident by the higher amount of TTN in the stratum corneum and
the smaller proportion in the viable epidermis and dermis (p< 0.05). The
Figure 2. Chromatograms of the tretinoin solution (10 μg mL1) (A), blank cream (B), blank gel (C), cotton (D), adhesive tape (E) and porcine skin (F) assessed during
the analytical validation of the method.
Table 3. Values of intra- and inter-day precision of tretinoin (TTN) assay in the
semisolid formulations.
Formulation Intra-day precision RSD (%) Inter-day precision RSD (%)
TTN-C 2.11 2.95
TTN-G 0.81 0.84
TTN-C: tretinoin-loaded cream; TTN-G: tretinoin-loaded gel; RSD: relative stan-
dard deviation.
Table 4. Accuracy of the method to assay TTN in different matrices. Data are
showed as R (%) and RSD (%) for B-C and B-G at 5.00; 10.00 and 15.00 μg mL1;
porcine skin, adhesive tape and cotton (þ TTN-C or TTN-G) at 2.50; 5.00 and
10.00 μg mL1 of drug as low, middle and high concentration, respectively.
Formulation Low concentration Middle concentration High concentration
R (%) RSD (%) R (%) RSD (%) R (%) RSD (%)
B-C 90.74 1.64 91.33 1.61 97.13 1.18
B-G 92.36 1.55 92.72 1.02 96.30 0.57
Porcine skin 89.41 5.40 89.40 5.55 89.47 4.88
Adhesive tape 95.25 4.18 100.31 5.40 96.81 3.97
Cotton þ TTN-C 106.80 2.18 107.70 1.95 114.30 4.01
Cotton þ TTN-G 113.90 3.40 103.65 2.19 102.47 2.19
R: recovery; RSD: relative standard deviation.
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below the LOQ, and it could not be quantified.
However, a significant difference (p < 0.05) between the formula-
tions was observed for the amount of drug penetrating all skin layers. The
penetration of TTN to the skin layers was higher for the gel than the
cream. This can be explained by the greater affinity of TTN (Log P¼ 5.66)
for the lipid components of the cream [40]. On the other hand, lipophilic
TTN has no affinity for the hydrophilic gel, facilitating its release to the5
skin. The influence of the viscosity on this result can be refuted since the
creams showed a lower consistency, as previously discussed. This lower
consistency could improve drug release and, consequently, the skin
penetration of TTN. To confirm the hypothesis that the affinity of TTN for
Figure 3. Amount of tretinoin (TTN) penetrated in different layers: stratum
corneum (SC), epidermis and dermis from TTN-C (TTN-loaded cream) and TTN-
G (TTN-loaded gel). Data represent the mean  SD (n ¼ 6). *Significant dif-
ference (p < 0.05) compared with the TTN-C.
D. de Oliveira et al. Heliyon 6 (2020) e03098the semisolid formulations explains the differences in skin penetration, a
release study was carried out using the same conditions used in the skin
permeation/penetration studies, replacing the skin discs with a mem-
brane disc. The experiment was carried out for 12 h. After this time, the
percentage of TTN released from the gel (33.42  6.62%) was higher
than the percentage released from the cream (2.42  0.72%) (p < 0.05).
These data confirmed our hypothesis, explaining the deeper penetration
of TTN from the gels (semisolid formulation) due to the faster release of
TTN to the stratum corneum surface compared to the cream.
4. Conclusion
In conclusion, a simple and reliable analytical method for quantifi-
cation of TTN in different matrices comprising porcine skin permeation/
penetration studies was validated. The method was specific, linear, pre-
cise, and accurate. Moreover, the method was applied in a real skin
permeation/penetration study, and it was able to assay TTN in the
different porcine skin layers (stratum corneum, viable epidermis, and
dermis), as well as differentiate the different skin penetration behaviours
of the formulations (gel and cream). Skin penetration of TTN was
dependent on the type of vehicle since the hydrogel resulted in deeper
penetration compared to the cream.
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